Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61R | melanoma | predicted - sensitive | NST-628 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, NST-628 treatment resulted in tumor regression in an intracranial melanoma cell line xenograft model harboring NRAS Q61R (Mol Cancer Ther (2023) 22 (12_Supplement): A089). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Abstract A089: NST-628 is a potent, fully brain-penetrant, RAS/MAPK pathway molecular glue inhibitor with efficacy in CNS tumor models | Full reference... |